Back to Journals » Cancer Management and Research » Volume 5

Nedaplatin: a cisplatin derivative in cancer chemotherapy

Authors Shimada M, Itamochi H, Kigawa J

Received 28 February 2013

Accepted for publication 12 April 2013

Published 8 May 2013 Volume 2013:5 Pages 67—76


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Muneaki Shimada,1 Hiroaki Itamochi,1 Junzo Kigawa2

1Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan; 2Cancer Center, Tottori University Hospital, Yonago, Japan

Abstract: Nedaplatin, a cisplatin analog, has been developed to decrease the toxicities induced by cisplatin, such as nephrotoxicity and gastrointestinal toxicity. The dose of nedaplatin is determined by body surface area, not by the area under the curve (AUC). The recommended therapeutic dose is 80–100 mg/m2, although the pharmacokinetic profile of nedaplatin is similar to that of carboplatin. In our preliminary study, there was a favorable correlation between AUC and creatinine clearance (CL), suggesting that renal function should be considered when nedaplatin is administered. Ishibashi’s formula, ie, DoseNDP = AUC × CLNDP, where CLNDP = 0.0738 × creatinine clearance + 4.47, would be predictable and useful for estimating the individual dose of nedaplatin. Several Phase II studies have suggested that nedaplatin might be a useful second analog, especially for patients with non-small cell lung cancer, esophageal cancer, uterine cervical cancer, head and neck cancer, or urothelial cancer. Further, nedaplatin was reported to be a useful chemotherapeutic agent with radiosensitizing properties; however, there is no Phase III study of nedaplatin, neither with chemotherapy nor with concurrent chemoradiotherapy, because nedaplatin is not commonly used throughout the world. Further evaluation in a randomized controlled trial is warranted to demonstrate definitively the activity of nedaplatin.

Keywords: nedaplatin, area under the curve, chemotherapy, concurrent chemoradiotherapy

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.